drugset / Trial / NCT01993472

Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer

NCT01993472 ↗

Phase 2 Terminated 308 enrolled Gu Yanhong
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy and safety of Andrographolides combined with Capecitabine in treatment of elderly patients with locally advanced or recurrent or metastasis inoperable colorectal cancer

Timeline

Start
2013-11
Primary completion
2016-12
Completion
2016-12

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual rate”

Drugs

EvaluationDrugModalityDoseRoute
Subject Andrographolides Unknown 500 mg —
Subject Capecitabine Small molecule 1250 mg/m2 —

Indications